GlassScriptPhysician profile
George S Tu
NPI 1720037898
$1,268.08
in general payments reported to CMS, 2019-2025
14 companies · $184 in 2025
The $184 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $14.35 · 2021: $146 · 2022: $326 · 2023: $268 · 2024: $142 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $576 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $575.74 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $626.63 | 2019-2023 | Da Vinci Surgical System |
| Noah Medical Corporation | $184.28 | 2025 | Galaxy |
| Inspire Medical Systems, INC. | $107.18 | 2024 | Inspire |
| Pulmonx Corporation | $76.40 | 2021 | |
| Exelixis INC. | $50.00 | 2021 | |
| Grifols USA, LLC | $40.31 | 2022-2023 | Prolastin-C Liquid |
| Inogen, INC. | $35.40 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Incyte Corporation | $31.54 | 2022 | |
| Celgene Corporation | $23.89 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $22.38 | 2022 | |
| Genentech USA, INC. | $21.10 | 2022 | |
| Merck Sharp & Dohme LLC | $18.09 | 2024 | Winrevair |
| Actelion Pharmaceuticals US, INC. | $16.53 | 2024 | Opsumit, Uptravi |
| Veran Medical Technologies, INC. | $14.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Tu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.